You are here

Pharming

Novartis buys priority review voucher from Pharming for discount price of $21M

Novartis buys priority review voucher from Pharming for discount price of $21M

Fierce Biotech

priority review vouchers

Flag link:

FDA approves Pharming drug for ultra-rare immunodeficiency disease

FDA approves Pharming drug for ultra-rare immunodeficiency disease

Endpoints

Flag link:

Former Novartis drug for ultra-rare disease gets speedy FDA review

Former Novartis drug for ultra-rare disease gets speedy FDA review

Endpoints

Flag link:

Corporate and regulatory developments over the Christmas period

Corporate and regulatory developments over the Christmas period

EP Vantage

Ono Pharmaceutical

Xyphos Biosciences

Flag link:

CSL accuses ex-exec, now at Pharming, of stealing trade secrets

CSL accuses ex-exec, now at Pharming, of stealing trade secrets

Pharmaforum

Flag link:

Novartis sells phase 3 rare disease drug to Pharming

Novartis sells phase 3 rare disease drug to Pharming

Fierce Biotech

Flag link: